Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)

By J. Schrader, S. Lüders, A. Kulschewski, F. Hammersen, K. Plate, J. Berger, W. Zidek, P. Dominiak, H. Diener. Stroke, 2005

777 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/188b2c9e7b5d02ce72f8b8ba188fedc96cd24575

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Epidemiology

Citations in the corpus

ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “a variety of other drugs in single trials and meta-analyses.(547,548)”
2013 ESH/ESC Guidelines for the management of arterial hypertension (2007, background): “a variety of other drugs in single trials and meta-analyses.(547,548)”
2007 ESH‐ESC Guidelines for the management of arterial hypertension (2007, background): “(307) In the MOSES trial (333) on about 1500 hypertensive patients with a previous cerebrovascular event comparison was made of treatment initiated by either eprosartan or the calcium antagonist nitrendipine.”
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, background): “a variety of other drugs in single trials and meta-analyses [547,548].”
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, background): “As demonstrated by the MOSES study [893], there are also results indicating differences”
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2018, neutral): “, 2005 (210) 15879332 Aim: To assess among hypertensive stroke pts, whether for the same level of BP control, eprosartan would be more effective than nitrendipine in reducing cerebrovascular and CV morbidity and mortality.”
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “randomized to eprosartan (an angiotensin receptor blocker) or nitrendipine (a calcium channel blocker).(38) BP reductions”